Proteomics

Dataset Information

0

Short Term Immune Response to IL6 inhibition (Tocilizumab)


ABSTRACT: we examined the effects of IL6 inhibition treatment on biologic molecular pathways in a 59 year old patient well diagnosed with RA with inadequate response to DMARD thus treated with tocilizumab. To assess the immunological outcome we used quantitative proteome analysis to evaluate changes in the proteome profile of different biologic pathways in leukocyte cell populations important to RA pathogenesis isolated by positive enrichment of CD14, CD4, CD8, CD19, and CD56.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Allan Stensballe  

PROVIDER: MSV000080787 | MassIVE | Wed Mar 29 15:02:00 BST 2017

SECONDARY ACCESSION(S): PXD002686

REPOSITORIES: MassIVE

Similar Datasets

2016-01-05 | PXD002686 | Pride
2022-05-31 | PXD033917 | Pride
2023-12-28 | PXD038810 | Pride
| PRJNA382983 | ENA
| 36170 | ecrin-mdr-crc
2017-05-26 | E-MTAB-5517 | biostudies-arrayexpress
| PRJNA383424 | ENA
2014-01-22 | E-GEOD-50646 | biostudies-arrayexpress
2010-07-21 | E-GEOD-23015 | biostudies-arrayexpress
2022-05-08 | GSE202367 | GEO